KIT and gastrointestinal stromal tumor: This approach has indeed delivered some successes, such as in lung tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) fusion treated with its inhibitor [5]; in non-small-cell lung cancers (NSCLCs) treated with molecules targeting BRAFV600E mutations [6]; and in gastrointestinal stromal tumours (GISTs) treated with c-Kit inhibitors [7].